See-Mode Technologies: Company Profile

Background

Overview

See-Mode Technologies is a MedTech company specializing in AI-driven ultrasound imaging solutions aimed at enhancing diagnostic accuracy and efficiency. Founded in 2017, the company is headquartered in Melbourne, Australia, with additional operations in Singapore. See-Mode's mission is to empower clinicians by providing advanced tools that streamline medical imaging processes, thereby improving patient outcomes. Its vision is to revolutionize healthcare delivery through innovative AI technologies that support clinicians in making faster and more accurate diagnoses.

Industry Significance

Operating within the medical imaging industry, See-Mode addresses critical challenges such as time-consuming manual analysis and variability in diagnostic reporting. By integrating AI into ultrasound imaging, the company contributes to the broader movement towards digital health solutions that enhance clinical workflows and patient care.

Key Strategic Focus

Core Objectives

See-Mode aims to develop AI-powered solutions that automate the analysis and reporting of ultrasound scans, thereby reducing manual workload, minimizing errors, and accelerating diagnostic processes.

Areas of Specialization

The company specializes in ultrasound imaging, focusing on applications in vascular studies, as well as breast and thyroid examinations.

Key Technologies Utilized

Deep Learning: Employed to interpret complex ultrasound images and detect anomalies.

Signal Processing: Used to enhance image quality and extract relevant features.

Text Recognition: Facilitates the generation of standardized reports from ultrasound images.

Primary Markets Targeted

See-Mode's solutions are designed for deployment in hospitals, imaging centers, and clinics worldwide, with a particular focus on markets in the United States, Australia, Singapore, New Zealand, and Europe.

Financials and Funding

Funding History

See-Mode Technologies has raised a total of $8 million over four funding rounds. The latest funding round was a Series A, led by MMV Europe & Asia-Pacific, completed on August 20, 2020.

Notable Investors

MassMutual Ventures

Blackbird Ventures

Cocoon Capital

SGInnovate

Utilization of Capital

The funds have been utilized to support product development, regulatory approvals, and market expansion efforts, enabling See-Mode to enhance its AI-powered ultrasound analysis software and extend its reach into new healthcare markets.

Pipeline Development

Key Pipeline Candidates

Augmented Vascular Analysis (AVA): An AI-driven software for automated analysis and reporting of vascular ultrasound scans. AVA has received regulatory approvals in multiple regions, including the United States, Australia, Singapore, and Europe.

Breast and Thyroid Ultrasound Solutions: AI-powered tools designed to detect and characterize lesions in breast and thyroid ultrasound images, aiming to improve diagnostic accuracy and efficiency. These solutions have received regulatory approvals in Australia, New Zealand, and Canada.

Stages of Development

AVA is commercially available in several markets, while the breast and thyroid ultrasound solutions are in the process of being integrated into clinical practice following their respective regulatory approvals.

Target Conditions

AVA: Vascular conditions, particularly those leading to stroke.

Breast and Thyroid Solutions: Detection and characterization of breast and thyroid lesions.

Anticipated Milestones

The company plans to expand the deployment of its breast and thyroid ultrasound solutions into additional markets and continue to enhance the capabilities of AVA through ongoing development efforts.

Technological Platform and Innovation

Proprietary Technologies

Deep Learning Algorithms: Developed to interpret ultrasound images and identify relevant features.

Signal Processing Techniques: Applied to enhance image quality and facilitate accurate analysis.

Automated Reporting Systems: Integrated to generate standardized reports from ultrasound scans.

Significant Scientific Methods

Multi-Reader Multi-Case (MRMC) Studies: Conducted to validate the performance of AI algorithms in clinical settings.

Clinical Validation Studies: Ongoing to assess the effectiveness of AI solutions in real-world medical environments.

Leadership Team

Key Executives

Dr. Milad Mohammadzadeh: Co-Founder and Director. Dr. Mohammadzadeh has a background in biomedical engineering and has been instrumental in the development and commercialization of See-Mode's AI solutions.

Dr. Sadaf Monajemi: Co-Founder. Dr. Monajemi brings expertise in medical imaging and has played a key role in the company's product development and regulatory strategy.

Key Contributions

Both founders have been pivotal in securing regulatory approvals, establishing strategic partnerships, and driving the company's mission to integrate AI into medical imaging for improved patient care.

Leadership Changes

In June 2025, See-Mode Technologies was acquired by RadNet, Inc., a leading provider of outpatient diagnostic imaging services. This acquisition aims to integrate See-Mode's AI-powered ultrasound solutions into RadNet's comprehensive portfolio, enhancing diagnostic capabilities and operational efficiency.

Competitor Profile

Market Insights and Dynamics

The medical imaging industry is experiencing rapid growth, driven by advancements in AI and machine learning technologies. The demand for automated imaging solutions is increasing as healthcare providers seek to improve diagnostic accuracy and efficiency.

Competitor Analysis

Viz.ai: Specializes in AI-powered solutions for stroke detection and triage, offering a platform that analyzes CT scans to identify large vessel occlusions.

Cercare Medical: Focuses on AI-driven diagnostic tools for radiology, providing software that assists in the detection and characterization of various medical conditions through imaging.

Strategic Collaborations and Partnerships

The acquisition by RadNet, Inc. represents a significant strategic collaboration, enabling See-Mode to leverage RadNet's extensive network and resources to expand the reach and impact of its AI-powered ultrasound solutions.

Operational Insights

Strategic Considerations

The integration of See-Mode's technologies into RadNet's operations is expected to enhance imaging capabilities, improve workflow efficiency, and support the delivery of high-quality patient care.

Competitive Advantages

See-Mode's AI solutions offer high levels of automation, reducing manual input and variability in reporting. The company's focus on regulatory approvals across multiple regions demonstrates a commitment to meeting diverse market requirements.

Strategic Opportunities and Future Directions

Strategic Roadmap

Post-acquisition, See-Mode aims to integrate its AI technologies into RadNet's imaging services, focusing on expanding the adoption of AI-powered ultrasound analysis across RadNet's facilities.

Future Business Directions

The company plans to continue developing AI solutions for other imaging modalities and medical conditions, leveraging its expertise to address additional challenges in the healthcare sector.

Opportunities for Expansion

With RadNet's support, See-Mode has the opportunity to scale its technologies more rapidly, reaching a broader patient population and contributing to the advancement of AI in medical imaging.